Blockchain-based health data exchange firm Avaneer Health secures $50M in seed funding

Avaneer Health, an interoperable healthcare data exchange company built on blockchain technology, has secured $50 million in seed funding from a number of large healthcare players.

Those backing the Chicago-based network include Aetna, Anthem, the Cleveland Clinic, Health Care Services Corporation, Sentara Healthcare, and the PNC Financial Services Group. The new money will be put into hiring additional team members and technology upgrades required to launch nationwide, the company said Jan. 13.

"Addressing administrative costs and creating a positive consumer experience requires connectivity and the type of data fluidity we have come to expect in other industries," Stuart Hanson, founding CEO of Avaneer Health, said in a statement. "We are very excited to jumpstart our network to enable healthcare organizations to work together with a foundation of trust to solve the 'last mile' problem in healthcare.”

The aforementioned companies, along with IBM, founded the startup in June 2021 and represent 80 million covered patients and 14 million visits per year.

Avaneer's member-based network initiates and streamlines care, helping payers exchange data, assess treatment eligibility, perform prior authorizations and other services.

"To achieve truly frictionless and seamless care, healthcare needs greater transparency and ease of navigation for all parties involved, particularly as we move toward greater adoption of value-based care,” said Tim Skeen, co-chair of Avaneer Health's Board of Directors and senior vice president and CIO of Sentara Healthcare.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.